Asahi Intecc said today it plans to begin direct sales of its coronary percutaneous transluminal coronary angioplasty guidewires in the US, which are currently only distributed by Abbott‘s (NYSE:ABT) vascular division.
The shift will take place on July 1, at which time Asahi’s entire portfolio of PTCA guidewires will be available directly from it, the Tustin, Calif.-based company said. All sales requests before the shift will be directed through Abbott, the company said.
Asahi said that in preparation for the direct offering, it has increased its sales, clinical, marketing and customer support teams. Representatives from the company will work directly with purchasers, including hospitals, group purchase organizations and integrated delivery networks.
“This represents a significant step to build Asahi Intecc as a leader in interventional cardiology in the United States. We look forward to working with physicians and hospitals to ensure a smooth transition from Abbott to Asahi for these important interventional tools,” prez & CEO Yoshi Terai said in a press release.
Late last month, Asahi won expanded FDA indications for its Corsair, Corsair Pro Microcatheters and coronary guide wires.